艾昆緯-印度藥品市場季度洞察報告

IndianPharmaceuticalMarket

QuarterlyInsights–Q12023(Jan-Mar)

ReportReleaseDate:May2023

Dataset:TSAMarch2023

?2023.Allrightsreserved.IQVIA?isaregisteredtrademarkofIQVIAIheUnitedStates,theEuropeanUnion,andvariousothercountries.

Marketreflectedgrowthof15%inQ12023

?OverallIPMmarketsize:?200KCr.(MATMar);?50,361Cr(Q1Mar2023)

?GrowthinSalesValuePreviousPeriodGrowth(‘PPG’):8%(MAT);15%(Q12023)

?ChronicTAsandAcuteTAsbothgrewatsamerate(15%PPG)inQ12023

?AmongstChronicTAs,Cardiacregisteredrobustgrowthof13%(PPG)andalsoledintermsofabsoluteincrementalvalue,followedbyChronicRespiratory29%(PPG)andNeuro/CNS13%(PPG).

?Anti-neoplast,Pain,Uro,Hormonesalsoregistereddoubledigitgrowth

?Anti-infectivesledthegrowthforAcuteTA’swithagrowthof28%(PPG).GastroandPainAcuteeachgrewat15%(PPG)

?RespiratoryAcutealsogrewindoubledigits

?VMNandDermagrewinsingledigits.

?Relativeperformance:IndianPharmaCosgrewfasterat16%(PPG)comparedtoMNCswhichgrewat10%(PPG)forQ12023

?Sun,Cipla,Mankind,AlkemreflectedgoodgrowthamongTopIndianPharmaCo’swhileAbbott,GSK,AstraZenecareflectedgoodgrowthsamongTopMNCPharmaCo’s

?Numberofnewlauncheshaveincreasedby26%in2023ascomparedto2022

MATMar2023vs.MATMar2022aswellasQtr.Jan-Mar2023vs.Qtr.Jan-Mar2022growth

Source:IQVIATSAMar2023

MATProgress,Val?、000Cr.

+8%

+11%186201

150157

136

20192020202120222023

QTRProgress,Val?’000Cr.

15%

10%

10%

8%

-2%

52

51

50

47

44

46

Q4’21Q1’22Q2’22Q3’22Q4’22Q1’23

1

Acute

Acutemarketgrowthof15%majorlyduetogrowthfromAI,PainandGItherapies

Acute

62%

Chronic

50.4

IPM

38%

Anti-Infectives

?Previousperiodgrowth:Value:28%;Unit:13%Sequentialquartergrowth:Value:0%;Unit:-4%

?Cephalosporins,whichcontributes~43%oftotalAItherapy,grewby-30%(PPG)growth.MacrolidesandQuinolonesgrewat16%(PPG)and8%(PPG)respectively.

?Azithromycincontributingto64%ofMacrolidesgrewat5%(PPG)

?HighgrowthwasseenfromAmpicillin/Amoxycillinat42%(PPG)

?Carbapenemsshowedgrowthof35%(PPG)majorlyduetoMeropenem36%(PPG)andFaropenem41%(PPG)

Respiratory(Acute)

?Previousperiodgrowth:Value:22%;Unit:11%Sequentialquartergrowth:Value:1%;Unit:-4%

?Coughpreparationscontributing~58%oftotaltherapysaleshaveshowngrowthof33%PPG.LevosalbutamolandCombhaveshownfastestgrowthof72%PPGinCoughprepmarket

?ColdPreparationsgrewat15%(PPG)majorlyduetoColdPrepLiqmarketwhichgrewat27%PPGandAntihistamines,systemicreflectedgoodgrowthof11%(PPG)

9%

19%

10%

45%

17%

AIPainGIOthersRespi

Pain

?Previousperiodgrowth:Value:15%;Unit:1%Sequentialquartergrowth:Value:-3%;Unit:-4%

?Antirheumatic,Nonsteroidalmarketwhichcontributesto44%ofPainmarketreflectedgrowthof14%(PPG)drivingthegrowthforPainmarket

?WhileAnti-Pyreticsamongstlargestcategorieshaveshowngrowthof20%(PPG),Musclerelaxantsamongstsmalleroneshasshowngrowthof12%(PPG)

?ParacetamolOralSolidshaveshownsingledigitgrowthat3%(PPG)whereasParaLiquidshaveshowngrowthof49%(PPG)

Gastro-Intestinal

?Previousperiodgrowth:Value:15%;Unit:8%Sequentialquartergrowth:Value:5%;Unit:14%

?AntipepticulcerantsandLaxativeshavereflectedgrowthof12%and16%(PPG)respectively

?Pantoprazole+DomperidoneandRabeprazole+Domperidonecontinuetogrowat10%and6%(PPG)respectively.

Qtr.Jan-Mar2023vs.Qtr.Jan-Mar2022growth

Source:IQVIATSAMar2023

2

16%

32%

17%

11%

23%

Chronic

Chronictherapiesalsodisplayedgrowthof15%(PPG)

Acute

62%

Chronic

50.4

IPM

38%

Cardiac

?Previousperiodgrowth:Value:13%;Unit:4%Sequentialquartergrowth:Value:1%;Unit:0%

?Statins&Hypotensivesbothgrewat16%(PPG)each.Theytogethercontribute~39%ofTAsales

?OtherCardiactherapiesviz.HypotensiveDiuretics,ARBhaveregisteredsingledigitgrowth

?Anticoagulantsgrewby8%(PPG)majorlyduetoTicagrelorgrowingat27%(PPG).However,Enoxaparinwhichcontributesto27%reflecteddegrowthof-4%(PPG)

Respiratory(Chronic)

?Previousperiodgrowth:Value:29%andUnit:39%Sequentialquartergrowth:Value:0%andUnit:-2%

?Montelukastandcombmarketgrewat22%(PPG)

?Montelukast+Levocetirizinegrewat13%(PPG)growth

?Bilastine+Montelukastshowedexceptionalgrowthof61%(PPG)

NeuroOthersRespiAnti-Diabetes

Anti-Diabetes

?Previousperiodgrowth:Value:9%;Unit:4%Sequentialquartergrowth:Value:0%Unit:-3%

?Glimepiride+Metformin(TraditionalOralAnti-Diabetes)contributingto~17%todiabetestherapyhasshowngrowthof11%(PPG)

?Glimipiride+Metformin+Voglibosecontributingto~6%todiabetestherapyhasalsoreflected11%(PPG)

?Vildagliptin+Metformingrewatsingledigitof1%(PPG)whereasVildagliptinde-grewat-13%(PPG)

?Insulinmarketshowedsingledigitgrowthof9%(PPG)

Neuro/CNS

?Previousperiodgrowth:Value:23%;Unit:13%Sequentialquartergrowth:Value:1%Unit3%

?Anti-DepressantandAnti-Epileptics,whichtogetherconstitute51%oftheTA,grewat14%(PPG)each

?Gabapentin+NortriptylinewithinAntiepilepticshasshownhighgrowthof22%(PPG)andBrivaracetamshowedfastestrateofgrowthof58%(PPG)

Cardiac

Qtr.Jan-Mar2023vs.Qtr.Jan-Mar2022growth

Source:IQVIATSAMar2023

3

(15%)36%33%

Geography

SouthandNorthzonescontinuetobehighestcontributingzones.ExtraUrbanmarketandMetrosgrewat15%each.Class1marketshowed14%growth

ZonalDynamics

Qtr.Jan-Mar23:?50,361Cr.,QOQGr(15%)

(16%)North

East(16%)

24%

27%

22%

27%

West(13%)

(14%)South

?South&Northareleadingzonesbycontribution;Southgrowingat14%PPGandNorthat16%PPGwithmostincrementalcomingfromUttarPradesh,Delhi,Telangana,KarnatakaandTamilNadu.

?Westzoneshowedgrowthof13%duetoMaharashtra,Gujarat,MadhyaPradeshregionsgrowingindoubledigit.However,MumbaiandGoagrewinsingledigit

?Eastzone’sgrowthof16%wasdrivenbyAssam,Bihar,WestBengal,Kolkata,OrissaandJharkhand.WhereasChhattisgarhgrewat8%(PPG)

?Amongstthetop15regions,UttarPradesh(13%PPG),Maharashtra(16%PPG),

TownClassAnalysis

Qtr.Jan-Mar23:?50,361Cr.,QOQGr(15%)

(15%)

Metro

31%

(14%)

Class1ExtraUrban

?